Petros Pharmaceuticals annual gross margin
2020
2021
2022
2023
2024
Petros Pharmaceuticals's gross margin was 76.28% for fiscal 2024.
View full Petros Pharmaceuticals company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | 76.28% | +4.29 pp |
| 2023 | 2023-12-31 | 71.98% | +10.19 pp |
| 2022 | 2022-12-31 | 61.79% | −17.73 pp |
| 2021 | 2021-12-31 | 79.52% | +21.85 pp |
| 2020 | 2020-12-31 | 57.67% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | 63.50% | −12.11 pp |
| Q3 2024 | 2024-09-30 | 81.79% | +7.56 pp |
| Q2 2024 | 2024-06-30 | 76.85% | −1.28 pp |
| Q1 2024 | 2024-03-31 | 76.11% | +140.03 pp |
| Q3 2023 | 2023-09-30 | 75.61% | −8.88 pp |
| Q2 2023 | 2023-06-30 | 74.23% | −6.61 pp |
| Q1 2023 | 2023-03-31 | 78.13% | −6.99 pp |
| Q3 2022 | 2022-09-30 | −63.92% | −147.92 pp |
| Q2 2022 | 2022-06-30 | 84.49% | +0.28 pp |
| Q1 2022 | 2022-03-31 | 80.84% | +40.28 pp |
| Q3 2021 | 2021-09-30 | 85.12% | +13.46 pp |
| Q2 2021 | 2021-06-30 | 84.00% | +23.25 pp |
| Q1 2021 | 2021-03-31 | 84.21% | +27.97 pp |
| Q4 2020 | 2020-12-31 | 40.56% | — |
| Q3 2020 | 2020-09-30 | 71.66% | — |
| Q2 2020 | 2020-06-30 | 60.74% | — |
| Q1 2020 | 2020-03-31 | 56.25% | — |
Across the available reported history, Petros Pharmaceuticals's gross margin increased from 71.98% to 76.28%, a change of +4.29 percentage points. The latest reported quarter, Q4 2024, shows 63.50%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Petros Pharmaceuticals filings at SEC.gov ↗